PharmaMar’s Aplidin Back On EMA’s Agenda After Conflict Of Interest Controversy

 
• By Neena Brizmohun
  
Business people discuss financial report in charts diagrams and graphs
The EMA is re-evaluating the marketing application for Aplidin (Shutterstock)

More from EU CHMP

More from Geography